New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT04126525
Summary
This study tested whether adding a newer drug called pyrotinib to standard chemotherapy and trastuzumab helps shrink tumors more effectively before surgery in women with HER2-positive breast cancer. The goal was to see if this combination leads to better outcomes by eliminating all cancer cells in the breast and lymph nodes before surgery. Researchers measured how many patients achieved complete disappearance of cancer cells after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renji Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.